Hong Kong SAR | Germantown, MD, USA | Suzhou Biobay, China, Sep 6, 2023 - Sirnaomics Ltd. (the “Company”; stock code: 2257, together with its subsidiaries, the “Group” or “Sirnaomics”), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, will present the latest developments on GalAhead™, a GalNAc-RNAi therapeutic platform, and its pipeline programs, at two international industry conferences taking place in September.

RNA Leaders USA Congress Presentation Details

• Presentation Title: GalAhead™: A Proprietary GalNAc-RNAi Therapeutic Platform to Downregulate Single and Multiple Genes
• Presenter: Jim Weterings, PhD, Sirnaomics Senior Director of Technology Innovation
• Time/Date: 5:05 pm-5:30 pm (EDT) on Wednesday, September 6, 2023
• Location: Hynes Convention Centre, Boston, USA
• Presentation content:
• Introduction to GalAhead, Sirnaomics’ GalNAc-RNAi therapeutic platform
• Validation of technology in vivo and in vitro
• Progress report on GalAhead-based programs

Oligonucleotide Chemistry & Therapeutics Europe 2023 Summit Presentation Details

• Presentation Title: GalAhead™: A Proprietary GalNAc-RNAi Therapeutic Platform to Downregulate Single and Multiple Genes
• Presenter: Jim Weterings, PhD, Sirnaomics Senior Director of Technology Innovation
• Time/Date: 9:55 am-10:20 am (CET) on Friday, September 15, 2023
• Location: Hotel Palace Berlin, Berlin, Germany
• Presentation content:
• Introduction to GalAhead, Sirnaomics’ GalNAc-RNAi therapeutic platform
• Validation of technology in vivo and in vitro
• Progress report on GalAhead-based programs

About Sirnaomics

Sirnaomics is an RNA therapeutics biopharmaceutical company with product candidates in preclinical and clinical stages that focuses on the discovery and development of innovative drugs for indications with medical needs and large market opportunities. Sirnaomics is the first clinical-stage RNA therapeutics company to have a strong presence in both Asia and the United States. Based on its proprietary delivery technologies: Polypeptide Nanoparticle Formulation and the 2nd generation of GalNAc conjugation, the Group has established an enriched drug candidate pipeline. Sirnaomics is currently holding a leadership position on advancing RNAi therapeutics for oncology application with multiple successes of its clinical programs for STP705 and STP707. STP122G represents the first drug candidate of GalAhead™ technology entering clinical development. With establishment of the Group’s manufacturing facility, Sirnaomics currently is undergoing a transition from a biotech company to a biopharma corporation. Learn more at: www.sirnaomics.com.

CONTACT: 

Investor Relations:

Nigel Yip, MBA

Chief Financial Officer, Sirnaomics

Email: [email protected]

U.S. Media Contact:

Alexis Feinberg        

Tel: +1 203 939 2225

Email: [email protected]

Asia Media Contact:

Heidi So

Tel: +852 2864 4826

Email: [email protected]